Ratings by Rodman & Renshaw (Seema Sheoran)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/3/2026 | Neurogene | NGNE | New Coverage | Buy (N/A) |
26.14 (37.31) |
42.73% | Details | |
| 4/14/2026 | CAMP4 Therapeutics Corp | CAMP | New Coverage | Buy (N/A) |
4.64 (3.71) |
-20.04% | Details | |
| 4/2/2026 | SAB Biotherapeutics | SABS | New Coverage | Buy (N/A) |
3.87 (3.54) |
-8.53% | Details | |
| 3/26/2026 | Enanta Pharmaceuticals | ENTA | New Coverage | Buy (N/A) |
12.17 (13.74) |
12.9% | Details | |
| 3/26/2026 | Sagimet Biosciences Inc | SGMT | New Coverage | Buy (N/A) |
4.62 (7.82) |
69.26% | Details |
